ProMIS Neurosciences’ Alzheimer’s therapy PMN310 attacks toxic forms of a protein linked to the disease but not normal forms, a preclinical-trial study indicates. Other therapies go after both forms of amyloid beta, giving PMN310 an important safety edge, ProMIS said. The study involved both human brain cells in a lab…
Pain Therapeutics’ Alzheimer’s therapy PTI-125 was safe, and patients tolerated it well, a Phase 1 clinical trial shows. The therapy is aimed at countering a faulty version of the filamin A protein. Scientists believe this abnormal version contributes to Alzheimer’s by facilitating the buildup of toxic nerve cell plaque and promoting…
BAN2401, an investigational anti-amyloid beta antibody therapy for Alzheimer’s disease, has failed to reach the primary endpoint of a Phase 2 clinical trial measured after 12 months of therapy. Study 201 will continue following the predefined protocol, where a comprehensive analysis will be performed after an 18-month treatment period. Final results…
Giving mice with Alzheimer’s a canola oil-rich diet for six months led to their memory and learning ability worsening, a study reports. The research, “Effect of canola oil consumption on memory, synapse and neuropathology in the triple transgenic mouse model of Alzheimer’s disease,” was published in the journal Scientific Reports.
Immungenetics AG is conducting a Phase 2 proof-of-concept clinical trial to investigate whether thiethylperazine — a treatment for nausea and vomiting in use since the 1960s — might help people with Alzheimer’s disease by working to slow or stop the early events that underlie disease progression. Thiethylperazine, sold…
Researchers in Wisconsin are looking for veterans with a family history of Alzheimer’s disease to determine whether fish oil can stop brain damage during the disorder’s early stages. “We know fish oil has beneficial effects on heart health,” Dr. Cindy Carlsson, the trial’s leading investigator and a researcher at the…
The National Institutes of Health (NIH) awarded a $4 million, five-year grant to a project that will investigate — among older residents of a multicultural New York neighborhood — the potential of a healthy and anti-inflammatory diet in lowering the risk of Alzheimer’s disease and cognitive decline. Yasmin Mossavar-Rahmani,…
As the number of Americans with Alzheimer’s disease continues to soar, the Global Alzheimer’s Platform (GAP) Foundation is establishing a new model to speed Alzheimer’s clinical trials and increase participation in research. To achieved its goal, the foundation is launching various measures to slash trial cycle times by up…
Probiodrug‘s PQ912 decreased markers of inflammation and damage in the nerve cell connections of Alzheimer’s patients, according to a Phase 2a clinical trial. The company will present the results of the SAPHIR trial, which covered the therapy’s safety and effectiveness, at the 10th Clinical Trials on Alzheimer’s Disease Conference in…
An antibody therapy that ProMIS Neurosciences is developing for Alzheimer’s formed a bond with only the harmful forms of amyloid beta clusters associated with the disease, an indication that it could be an effective treatment, according to a preclinical-trial study. A good sign was that PMN310 didn’t bind to the forms…
Get regular updates to your inbox.